Real world data on vaccine effectiveness in 5 to 11 year olds
16 March 2022
- Data shows high effectiveness of the Pfizer-BioNTech vaccine among adolescents before Omicron became the predominant variant, and with data from adults demonstrating higher protection against more severe outcomes
- The findings in this report also align with studies among adults that report lower vaccine effectiveness during Omicron variant predominance and an increase in vaccine effectiveness after receipt of a third vaccine dose
- The report provides real world evidence of protection by the Pfizer-BioNTech vaccine against COVID-19–associated emergency department and urgent care encounters and hospitalisations among children and adolescents aged 5–17 years and supports the role of third (booster) doses in maintaining high levels of vaccine effectiveness in the setting of Omicron predominance
- “We now have compelling evidence that vaccines and, for 16- and 17-year-olds, boosters, provide important protection for both children and adolescents — data-driven information that parents should take into consideration when making decisions for their family,”
Shaun Grannis
Vice President for Data and Analytics
Regenstrief Institute
Click here to learn more.
About SVMPharma
SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.
About DISTILL
DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.
For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com
Ref: RWEMAR2022HBB